Skip to content
The Policy VaultThe Policy Vault

Revlimid — Medica

Peripheral T-Cell Lymphomas

Initial criteria

  • age ≥ 18 years
  • Patient has tried at least one other regimen (examples provided)

Approval duration

3 years